New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against…
Vaxart, Inc. a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced at Vaxart’s key opinion…
Read More...
Read More...
